Free Preview of Members-Only Content

To view the requested intelligence, you must be a Stratfor.com member.

The World Health Organization announced Feb. 1 that the current strains of influenza circulating in Canada and the United States are indicating "elevated resistance" to antiviral drug Tamiflu, severely complicating efforts to prepare for a possible pandemic.

The World Health Organization (WHO) announced Feb. 1 that anti-viral drug Oseltamivir, marketed as Tamiflu by the Swiss pharmaceutical company Roche and U.S.-based Gilead Sciences Inc., is starting to show signs of ineffectiveness against the influenza-A viruses, in particular the current H1N1 strain that is affecting North America. The resistance of influenza-A to Tamiflu was already reported in Europe during testing conducted in November and December 2007.

Stratfor Members, please log in at the top left hand corner

Get Stratfor's Free Intelligence

Objective Facts and Non-partisan Analysis

* Email Address:

Stratfor delivers premier analysis and insightful intelligence on the events and issues that shape your world! Become part of a community that wants to understand what's really happening in the world, doesn't have time for fluff, partisanship, and noisy clutter. Enjoy free Intelligence written by:

Dr. George Friedman – Geopolitics
Fred Burton & Scott Stewart - Terrorism & Security

Delivered to your inbox FREE!

Get right to the salient points and receive:

Situational Awareness - What's happening that you need to know?
Analysis - What do today's events mean to you?
Insight – no partisan agenda & no ideological bias

Stratfor is the world's leading private sector source of geopolitical intelligence. Sign up today and enjoy free intelligence.

* Email Address:

* Email Address:

"I have been a member for about three weeks and find your updates and analyses outstanding. I have referred a number of friends to the site and recommended they become a member. Very nice work."

—David Kretschmer
Healthcare Executive

"Without peer in open source intelligence."

—Gen. Thomas Wilkerson USMC (retired)
CEO United States Naval Institute

"I think you do a great job with what you produce. Keep up the great writing and analysis, it's as good or better than a great deal of the classified intel briefings I used to get."

—Herb Riessen
Brigadier General (retired)

"As a subscriber paid up for the next few years, I find your thinking very refreshing and very rewarding for me personally. I have always thought the mainstream news media were a day late and a dollar short on most subtle issues. And of course elected political leaders were only interested in discussing issues in a way that would help their re-election chances."

—Ed Paules
SVP Capital Markets

"Kudos to you guys for another excellent piece. Your premium subscription is my most important out of pocket professional expense. Your insight and analysis — and willingness to admit your infrequent missed forecast — makes STRATFOR the best daily resource I have."

—Jay A. Carroll
Lt. Col. & Certified Protection Professional

Satisfaction Guaranteed!

30 days risk free. If you're not satisfied with Stratfor, we'll refund 100% of your purchase price!

Your order information is securely encrypted

Questions? Problems with your order? Contact us by email at service@stratfor.com or call 512-744-4300, 9–5 CT, M–F.

User login

Navigation

Free Preview of Members-Only Content